BACKGROUND: Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a challenge to the implementation of vaccine delivery. This field trial examines the effectiveness of school-based clinics for vaccine delivery before an epidemic caused by 3 new influenza virus variants not contained in the vaccine. METHODS: Live attenuated influenza vaccine (LAIV) was offered to eligible children in elementary schools of eastern Bell County, Texas. Age-specific rates of medically attended acute respiratory illness for health plan members at the intervention site were compared with those for members at comparison sites during the epidemic, defined by viral surveillance at all sites. RESULTS: Almost 48% of children in elementary schools were vaccinated. Significant herd protection attributed to LAIV was detected for all age groups except 12-17-year-old students, who were not offered free vaccine. Approximately 2500 medical encounters were prevented at the intervention site. Inactivated vaccine provided marginal protection against the epidemic viruses. CONCLUSIONS: LAIV delivered to elementary-school children before an epidemic caused by 3 new variant influenza viruses generated significant cross-protection for the recipients and indirect (herd) protection for the community.
BACKGROUND:Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a challenge to the implementation of vaccine delivery. This field trial examines the effectiveness of school-based clinics for vaccine delivery before an epidemic caused by 3 new influenza virus variants not contained in the vaccine. METHODS: Live attenuated influenza vaccine (LAIV) was offered to eligible children in elementary schools of eastern Bell County, Texas. Age-specific rates of medically attended acute respiratory illness for health plan members at the intervention site were compared with those for members at comparison sites during the epidemic, defined by viral surveillance at all sites. RESULTS: Almost 48% of children in elementary schools were vaccinated. Significant herd protection attributed to LAIV was detected for all age groups except 12-17-year-old students, who were not offered free vaccine. Approximately 2500 medical encounters were prevented at the intervention site. Inactivated vaccine provided marginal protection against the epidemic viruses. CONCLUSIONS:LAIV delivered to elementary-school children before an epidemic caused by 3 new variant influenza viruses generated significant cross-protection for the recipients and indirect (herd) protection for the community.
Authors: R B Belshe; W C Gruber; P M Mendelman; I Cho; K Reisinger; S L Block; J Wittes; D Iacuzio; P Piedra; J Treanor; J King; K Kotloff; D I Bernstein; F G Hayden; K Zangwill; L Yan; M Wolff Journal: J Pediatr Date: 2000-02 Impact factor: 4.406
Authors: Pedro A Piedra; Manjusha J Gaglani; Mark Riggs; Gayla Herschler; Charles Fewlass; Matt Watts; Claudia Kozinetz; Colin Hessel; W Paul Glezen Journal: Pediatrics Date: 2005-09 Impact factor: 7.124
Authors: Niranjan Bhat; Jennifer G Wright; Karen R Broder; Erin L Murray; Michael E Greenberg; Maleeka J Glover; Anna M Likos; Drew L Posey; Alexander Klimov; Stephen E Lindstrom; Amanda Balish; Marie-jo Medina; Teresa R Wallis; Jeannette Guarner; Christopher D Paddock; Wun-Ju Shieh; Sherif R Zaki; James J Sejvar; David K Shay; Scott A Harper; Nancy J Cox; Keiji Fukuda; Timothy M Uyeki Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: M Elizabeth Halloran; Ira M Longini; Manjusha J Gaglani; Pedro A Piedra; Haitao Chu; Gayla B Herschler; W Paul Glezen Journal: Am J Epidemiol Date: 2003-08-15 Impact factor: 4.897
Authors: Manjusha J Gaglani; Pedro A Piedra; Gayla B Herschler; Melissa E Griffith; Claudia A Kozinetz; Mark W Riggs; Charles Fewlass; M Elizabeth Halloran; Ira M Longini; W Paul Glezen Journal: Arch Pediatr Adolesc Med Date: 2004-01
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Pedro A Piedra; Manjusha J Gaglani; Claudia A Kozinetz; Gayla Herschler; Mark Riggs; Melissa Griffith; Charles Fewlass; Matt Watts; Colin Hessel; Julie Cordova; W Paul Glezen Journal: Vaccine Date: 2005-02-18 Impact factor: 3.641
Authors: Annika M Hofstetter; Karthik Natarajan; Daniel Rabinowitz; Raquel Andres Martinez; David Vawdrey; Stephen Arpadi; Melissa S Stockwell Journal: Am J Public Health Date: 2013-05-16 Impact factor: 9.308
Authors: Laetitia Gerlier; Mark Lamotte; Sofia Dos Santos Mendes; Oliver Damm; Markus Schwehm; Martin Eichner Journal: Paediatr Drugs Date: 2016-08 Impact factor: 3.022
Authors: Kenneth J Smith; Mary Patricia Nowalk; Angela Wateska; Shawn T Brown; Jay V DePasse; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman Journal: Am J Prev Med Date: 2017-04-18 Impact factor: 5.043
Authors: Jennifer L Moss; Ashley L Feld; Brittany O'Malley; Pamela Entzel; Jennifer S Smith; Melissa B Gilkey; Noel T Brewer Journal: J Sch Health Date: 2014-06 Impact factor: 2.118
Authors: Timothy R Peters; Beverly M Snively; Cynthia K Suerken; Elizabeth Blakeney; Lauren Vannoy; Katherine A Poehling Journal: Vaccine Date: 2014-10-01 Impact factor: 3.641